Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	protein tyrosine kinase activity	FLT3 MATK ROR1 TNK2 MAP2K6 ZAP70	3.37e-05	145	84	6	GO:0004713
GeneOntologyMolecularFunction	DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity	TOP2A TOP2B	1.04e-04	4	84	2	GO:0003918
GeneOntologyMolecularFunction	pancreatic polypeptide receptor activity	NPY4R2 NPY4R	1.04e-04	4	84	2	GO:0001602
GeneOntologyMolecularFunction	DNA/RNA hybrid binding	POLR3B POLR3A	1.73e-04	5	84	2	GO:0071667
GeneOntologyMolecularFunction	DNA topoisomerase activity	TOP2A TOP2B	4.82e-04	8	84	2	GO:0003916
GeneOntologyBiologicalProcess	regulation of type I interferon production	ILRUN CUL3 FLT3 TRAF6 POLR3B STAT1 POLR3A	1.90e-06	141	85	7	GO:0032479
GeneOntologyBiologicalProcess	type I interferon production	ILRUN CUL3 FLT3 TRAF6 POLR3B STAT1 POLR3A	2.29e-06	145	85	7	GO:0032606
GeneOntologyBiologicalProcess	positive regulation of single stranded viral RNA replication via double stranded DNA intermediate	TOP2A TOP2B	1.68e-05	2	85	2	GO:0045870
GeneOntologyBiologicalProcess	positive regulation of type I interferon production	FLT3 TRAF6 POLR3B STAT1 POLR3A	2.11e-05	81	85	5	GO:0032481
Domain	-	TOP2A TOP2B	1.90e-05	2	82	2	3.40.50.670
Domain	DTHCT	TOP2A TOP2B	1.90e-05	2	82	2	IPR012542
Domain	DNA_gyraseB	TOP2A TOP2B	1.90e-05	2	82	2	PF00204
Domain	-	TOP2A TOP2B	1.90e-05	2	82	2	3.90.199.10
Domain	TopoIIA_CS	TOP2A TOP2B	1.90e-05	2	82	2	IPR018522
Domain	Topo_IIA	TOP2A TOP2B	1.90e-05	2	82	2	IPR001241
Domain	DNA_topoisoIV	TOP2A TOP2B	1.90e-05	2	82	2	PF00521
Domain	Topo_IIA_A/C_ab	TOP2A TOP2B	1.90e-05	2	82	2	IPR013758
Domain	Topo_IIA_A_a	TOP2A TOP2B	1.90e-05	2	82	2	IPR013757
Domain	Topo_IIA_cen_dom	TOP2A TOP2B	1.90e-05	2	82	2	IPR013759
Domain	TOP4c	TOP2A TOP2B	1.90e-05	2	82	2	SM00434
Domain	TOP2c	TOP2A TOP2B	1.90e-05	2	82	2	SM00433
Domain	Topo_IIA-like_dom	TOP2A TOP2B	1.90e-05	2	82	2	IPR013760
Domain	Topo_IIA_bsu_dom2	TOP2A TOP2B	1.90e-05	2	82	2	IPR013506
Domain	DTHCT	TOP2A TOP2B	1.90e-05	2	82	2	PF08070
Domain	-	TOP2A TOP2B	1.90e-05	2	82	2	1.10.268.10
Domain	NPY4_rcpt	NPY4R2 NPY4R	1.90e-05	2	82	2	IPR001933
Domain	TOPRIM_C	TOP2A TOP2B	1.90e-05	2	82	2	IPR031660
Domain	TOPRIM_C	TOP2A TOP2B	1.90e-05	2	82	2	PF16898
Domain	Topo_IIA_A/C	TOP2A TOP2B	1.90e-05	2	82	2	IPR002205
Domain	TOPOISOMERASE_II	TOP2A TOP2B	1.90e-05	2	82	2	PS00177
Domain	ATPase_dyneun-rel_AAA	VWA8 DNAH8 DNAH9	2.87e-05	14	82	3	IPR011704
Domain	AAA_5	VWA8 DNAH8 DNAH9	2.87e-05	14	82	3	PF07728
Domain	Tyr_kinase_cat_dom	FLT3 MATK ROR1 TNK2 ZAP70	4.25e-05	88	82	5	IPR020635
Domain	TyrKc	FLT3 MATK ROR1 TNK2 ZAP70	4.25e-05	88	82	5	SM00219
Domain	Arg_repress_C-like	TOP2A TOP2B	5.70e-05	3	82	2	IPR024946
Domain	-	TOP2A TOP2B	5.70e-05	3	82	2	3.30.1360.40
Domain	PROTEIN_KINASE_TYR	FLT3 MATK ROR1 TNK2 ZAP70	6.77e-05	97	82	5	PS00109
Domain	Tyr_kinase_AS	FLT3 MATK ROR1 TNK2 ZAP70	6.77e-05	97	82	5	IPR008266
Domain	Toprim	TOP2A TOP2B	1.14e-04	4	82	2	PF01751
Domain	Toprim_domain	TOP2A TOP2B	1.14e-04	4	82	2	IPR006171
Domain	TOPRIM	TOP2A TOP2B	1.14e-04	4	82	2	PS50880
Domain	Pkinase_Tyr	FLT3 MATK ROR1 TNK2 ZAP70	2.59e-04	129	82	5	PF07714
Domain	Ser-Thr/Tyr_kinase_cat_dom	FLT3 MATK ROR1 TNK2 ZAP70	3.54e-04	138	82	5	IPR001245
Domain	DHC_N1	DNAH8 DNAH9	5.24e-04	8	82	2	PF08385
Domain	Dynein_heavy_dom-1	DNAH8 DNAH9	5.24e-04	8	82	2	IPR013594
Domain	LAM_G_DOMAIN	FAT2 LAMA5 EGFLAM	6.16e-04	38	82	3	PS50025
Domain	NPY_rcpt	NPY4R2 NPY4R	6.72e-04	9	82	2	IPR000611
Domain	Laminin_G_2	FAT2 LAMA5 EGFLAM	7.17e-04	40	82	3	PF02210
Domain	LamG	FAT2 LAMA5 EGFLAM	9.49e-04	44	82	3	SM00282
Domain	Dynein_heavy_chain_D4_dom	DNAH8 DNAH9	1.67e-03	14	82	2	IPR024317
Domain	Dynein_HC_stalk	DNAH8 DNAH9	1.67e-03	14	82	2	IPR024743
Domain	Dynein_heavy_dom-2	DNAH8 DNAH9	1.67e-03	14	82	2	IPR013602
Domain	DHC_N2	DNAH8 DNAH9	1.67e-03	14	82	2	PF08393
Domain	MT	DNAH8 DNAH9	1.67e-03	14	82	2	PF12777
Domain	AAA_8	DNAH8 DNAH9	1.67e-03	14	82	2	PF12780
Domain	DHC_fam	DNAH8 DNAH9	1.93e-03	15	82	2	IPR026983
Domain	Dynein_heavy	DNAH8 DNAH9	1.93e-03	15	82	2	PF03028
Domain	Dynein_heavy_dom	DNAH8 DNAH9	1.93e-03	15	82	2	IPR004273
Domain	Laminin_G	FAT2 LAMA5 EGFLAM	2.12e-03	58	82	3	IPR001791
Domain	HATPase_c	TOP2A TOP2B	2.78e-03	18	82	2	SM00387
Domain	HATPase_c	TOP2A TOP2B	3.10e-03	19	82	2	PF02518
Domain	-	TOP2A TOP2B	3.44e-03	20	82	2	3.30.565.10
Domain	AAA	VWA8 ABCA12 DNAH8 DNAH9	3.72e-03	144	82	4	SM00382
Domain	AAA+_ATPase	VWA8 ABCA12 DNAH8 DNAH9	3.72e-03	144	82	4	IPR003593
Domain	-	TOP2A TOP2B	3.79e-03	21	82	2	3.30.230.10
Domain	HATPase_C	TOP2A TOP2B	3.79e-03	21	82	2	IPR003594
Domain	Ribosomal_S5_D2-typ_fold_subgr	TOP2A TOP2B	4.15e-03	22	82	2	IPR014721
Pubmed	Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function.	TARDBP ARHGEF40 POLR3B PTPN14 DDX18 HNRNPM KDM2A AKAP10 ERI1 CDC5L DDX41 TOP2A TOP2B STAT1 VCL POLR3A	1.58e-07	1353	85	16	29467282
Pubmed	Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.	ARHGEF40 PTPN14 AKAP17A VWA8 ABCA12 DDX18 AOX1 HNRNPM HSD11B1 RAPGEF2 DDX41 INO80D TOP2A ADCY9	5.15e-07	1116	85	14	31753913
Pubmed	USP7 targets XIAP for cancer progression: Establishment of a p53-independent therapeutic avenue for glioma.	EFCAB5 FAT2 HNRNPM CDC5L NEB TOP2A TOP2B	1.80e-06	234	85	7	36243803
Pubmed	The protein tyrosine kinase family of the human genome.	FLT3 MATK ROR1 TNK2 ZAP70	1.93e-06	83	85	5	11114734
Pubmed	SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.	HNRNPM LAMA5 KDM2A CDC5L DDX41 TOP2A VCL	2.79e-06	250	85	7	33536335
Pubmed	DNA topoisomerase II is dispensable for oocyte meiotic resumption but is essential for meiotic chromosome condensation and separation in mice.	TOP2A TOP2B	5.90e-06	2	85	2	24048577
Pubmed	Mutations in POLR3A and POLR3B are a major cause of hypomyelinating leukodystrophies with or without dental abnormalities and/or hypogonadotropic hypogonadism.	POLR3B POLR3A	5.90e-06	2	85	2	23355746
Pubmed	Use of divalent metal ions in the dna cleavage reaction of human type II topoisomerases.	TOP2A TOP2B	5.90e-06	2	85	2	19222228
Pubmed	POLR3A and POLR3B Mutations in Unclassified Hypomyelination.	POLR3B POLR3A	5.90e-06	2	85	2	26011300
Pubmed	Evidence for a mutant allele of the gene for DNA topoisomerase II in adriamycin-resistant P388 murine leukemia cells.	TOP2A TOP2B	5.90e-06	2	85	2	2555055
Pubmed	Characterization of cDNA encoding the mouse DNA topoisomerase II that can complement the budding yeast top2 mutation.	TOP2A TOP2B	5.90e-06	2	85	2	1331984
Pubmed	Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase IIα to IIβ in human stem cell derived cardiomyocytes.	TOP2A TOP2B	5.90e-06	2	85	2	31106979
Pubmed	A biochemical analysis of topoisomerase II alpha and beta kinase activity found in HIV-1 infected cells and virus.	TOP2A TOP2B	5.90e-06	2	85	2	16091284
Pubmed	Mining topoisomerase isoforms in gastric cancer.	TOP2A TOP2B	5.90e-06	2	85	2	32535049
Pubmed	Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development.	TOP2A TOP2B	5.90e-06	2	85	2	1380833
Pubmed	Different patterns of cerebellar abnormality and hypomyelination between POLR3A and POLR3B mutations.	POLR3B POLR3A	5.90e-06	2	85	2	23643445
Pubmed	Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation Via LAMA5/ITGA4 Axis.	LAMA5 ITGA4	5.90e-06	2	85	2	38154529
Pubmed	Involvement of human topoisomerase II isoforms in HIV-1 reverse transcription.	TOP2A TOP2B	5.90e-06	2	85	2	23399433
Pubmed	Enhanced processing of UVA-irradiated DNA by human topoisomerase II in living cells.	TOP2A TOP2B	5.90e-06	2	85	2	15044480
Pubmed	C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo.	TOP2A TOP2B	5.90e-06	2	85	2	17526531
Pubmed	DNA topoisomerase II distribution in mouse preimplantation embryos.	TOP2A TOP2B	5.90e-06	2	85	2	11835579
Pubmed	Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations.	POLR3B POLR3A	5.90e-06	2	85	2	25339210
Pubmed	Mutations in POLR3A and POLR3B encoding RNA Polymerase III subunits cause an autosomal-recessive hypomyelinating leukoencephalopathy.	POLR3B POLR3A	5.90e-06	2	85	2	22036171
Pubmed	Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes.	TOP2A TOP2B	5.90e-06	2	85	2	2556712
Pubmed	The leukodystrophy mutation Polr3b R103H causes homozygote mouse embryonic lethality and impairs RNA polymerase III biogenesis.	POLR3B POLR3A	5.90e-06	2	85	2	31221184
Pubmed	Using a biochemical approach to identify the primary dimerization regions in human DNA topoisomerase IIalpha.	TOP2A TOP2B	5.90e-06	2	85	2	10473615
Pubmed	Cellular distribution of mammalian DNA topoisomerase II is determined by its catalytically dispensable C-terminal domain.	TOP2A TOP2B	5.90e-06	2	85	2	9224616
Pubmed	DNA damage response during chromatin remodeling in elongating spermatids of mice.	TOP2A TOP2B	5.90e-06	2	85	2	18032420
Pubmed	Maternal topoisomerase II alpha, not topoisomerase II beta, enables embryonic development of zebrafish top2a-/- mutants.	TOP2A TOP2B	5.90e-06	2	85	2	22111588
Pubmed	Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.	TOP2A TOP2B	5.90e-06	2	85	2	17578914
Pubmed	Diffuse hypomyelination is not obligate for POLR3-related disorders.	POLR3B POLR3A	5.90e-06	2	85	2	27029625
Pubmed	Investigation of Potential Mechanisms Associated with Non-small Cell Lung Cancer.	TOP2A CCNB1	5.90e-06	2	85	2	32048869
Pubmed	Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively.	TOP2A TOP2B	5.90e-06	2	85	2	1309226
Pubmed	Kinetic analysis of human topoisomerase IIalpha and beta DNA binding by surface plasmon resonance.	TOP2A TOP2B	5.90e-06	2	85	2	14596941
Pubmed	Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity.	TOP2A TOP2B	5.90e-06	2	85	2	17361331
Pubmed	Molecular cloning and characterization of the human topoisomerase IIalpha and IIbeta genes: evidence for isoform evolution through gene duplication.	TOP2A TOP2B	5.90e-06	2	85	2	10095062
Pubmed	Functional compatibility between isoform alpha and beta of type II DNA topoisomerase.	TOP2A TOP2B	5.90e-06	2	85	2	14996935
Pubmed	Structural organization of the human TOP2A and TOP2B genes.	TOP2A TOP2B	5.90e-06	2	85	2	9795238
Pubmed	The distribution of DNA topoisomerase II isoforms in differentiated adult mouse tissues.	TOP2A TOP2B	5.90e-06	2	85	2	8241259
Pubmed	Dynamics of human DNA topoisomerases IIalpha and IIbeta in living cells.	TOP2A TOP2B	5.90e-06	2	85	2	11927602
Pubmed	Topoisomerase II binds importin alpha isoforms and exportin/CRM1 but does not shuttle between the nucleus and cytoplasm in proliferating cells.	TOP2A TOP2B	5.90e-06	2	85	2	17182034
Pubmed	Natural variation in a single amino acid substitution underlies physiological responses to topoisomerase II poisons.	TOP2A TOP2B	5.90e-06	2	85	2	28700616
Pubmed	Predictors and mechanisms of epilepsy occurrence in cerebral gliomas: What to look for in clinicopathology.	TOP2A TOP2B	5.90e-06	2	85	2	28087392
Pubmed	Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.	TOP2A TOP2B	5.90e-06	2	85	2	28472494
Pubmed	Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia.	TOP2A TOP2B	5.90e-06	2	85	2	32218491
Pubmed	The transcript expression levels of HNRNPM, HNRNPA0 and AKAP17A splicing factors may be predictively associated with ageing phenotypes in human peripheral blood.	AKAP17A HNRNPM	5.90e-06	2	85	2	31292793
Pubmed	Ciprofloxacin impairs mitochondrial DNA replication initiation through inhibition of Topoisomerase 2.	TOP2A TOP2B	5.90e-06	2	85	2	30169847
Pubmed	The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.	TOP2A TOP2B	5.90e-06	2	85	2	9155056
Pubmed	A study of the topoisomerase II activity in HIV-1 replication using the ferrocene derivatives as probes.	TOP2A TOP2B	5.90e-06	2	85	2	16712776
Pubmed	Active heterodimers are formed from human DNA topoisomerase II alpha and II beta isoforms.	TOP2A TOP2B	5.90e-06	2	85	2	8710863
Pubmed	Distinct expression patterns for type II topoisomerases IIA and IIB in the early foetal human telencephalon.	TOP2A TOP2B	5.90e-06	2	85	2	26612825
Pubmed	Discrete localization of different DNA topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions.	TOP2A TOP2B	5.90e-06	2	85	2	8299728
Pubmed	Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.	CUL3 TARDBP POLR3B DDX18 KDM2A CDC5L MED1 DDX41 TOP2A TOP2B STAT1 POLR3A	6.58e-06	1014	85	12	32416067
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	TARDBP PTPN14 KDM2A CDC5L MED1 RUFY1 TOP2A STAT1 VCL	8.10e-06	549	85	9	38280479
Pubmed	Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation.	TARDBP DDX18 HNRNPM PUS1 APOB CDC5L DDX41 PLEKHA7 TOP2A TOP2B STAT1 VCL POLR3A ARMC8	8.80e-06	1425	85	14	30948266
Pubmed	A Global Analysis of the Receptor Tyrosine Kinase-Protein Phosphatase Interactome.	SMG1 AKAP17A ROR1 MTMR8 APOB HSD11B1 PLEKHA7 DNAH8	9.05e-06	420	85	8	28065597
Pubmed	The E3 ubiquitin ligase HECTD1 contributes to cell proliferation through an effect on mitosis.	CUL3 POLR3B AKAP17A DDX18 HNRNPM ERI1 CDC5L MED1 TOP2A TOP2B	1.66e-05	759	85	10	35915203
Pubmed	Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis.	TOP2A TOP2B	1.77e-05	3	85	2	11136718
Pubmed	Endocrine and Growth Abnormalities in 4H Leukodystrophy Caused by Variants in POLR3A, POLR3B, and POLR1C.	POLR3B POLR3A	1.77e-05	3	85	2	33005949
Pubmed	Proteolytic degradation of topoisomerase II (Top2) enables the processing of Top2·DNA and Top2·RNA covalent complexes by tyrosyl-DNA-phosphodiesterase 2 (TDP2).	TOP2A TOP2B	1.77e-05	3	85	2	24808172
Pubmed	Identification of functional nuclear export sequences in human topoisomerase IIalpha and beta.	TOP2A TOP2B	1.77e-05	3	85	2	12821127
Pubmed	Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism.	TARDBP TBC1D1	1.77e-05	3	85	2	20660762
Pubmed	Vinculin regulates osteoclast function.	CTSK VCL	1.77e-05	3	85	2	24675074
Pubmed	POLR3-Related Leukodystrophy	POLR3B POLR3A	1.77e-05	3	85	2	22855961
Pubmed	Human topoisomerase IIalpha and IIbeta interact with the C-terminal region of p53.	TOP2A TOP2B	1.77e-05	3	85	2	10666337
Pubmed	The role of Nav1.7 and methylglyoxal-mediated activation of TRPA1 in itch and hypoalgesia in a murine model of type 1 diabetes.	TRPA1 SCN9A	1.77e-05	3	85	2	31285762
Pubmed	Nucleophagy contributes to genome stability through degradation of type II topoisomerases A and B and nucleolar components.	TOP2A TOP2B	1.77e-05	3	85	2	36633090
Pubmed	Protein kinase C delta activates topoisomerase IIalpha to induce apoptotic cell death in response to DNA damage.	TOP2A TOP2B	1.77e-05	3	85	2	16611985
Pubmed	Cloning and functional expression of cDNAs encoding human and rat pancreatic polypeptide receptors.	NPY4R2 NPY4R	1.77e-05	3	85	2	8643460
Pubmed	Stimulation of Pol III-dependent 5S rRNA and U6 snRNA gene expression by AP-1 transcription factors.	POLR3B POLR3A	1.77e-05	3	85	2	28488757
Pubmed	Nuclear interactions of topoisomerase II alpha and beta with phospholipid scramblase 1.	TOP2A TOP2B	1.77e-05	3	85	2	17567603
Pubmed	Novel oxygen sensing mechanism in the spinal cord involved in cardiorespiratory responses to hypoxia.	TRPA1 NOS1	1.77e-05	3	85	2	35333571
Pubmed	DNA topoisomerase II inhibitors induce macrophage ABCA1 expression and cholesterol efflux-an LXR-dependent mechanism.	TOP2A TOP2B	1.77e-05	3	85	2	23466610
Pubmed	Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities.	TOP2A TOP2B	1.77e-05	3	85	2	9049244
Pubmed	A cancer-associated RNA polymerase III identity drives robust transcription and expression of snaR-A noncoding RNA.	POLR3B POLR3A	1.77e-05	3	85	2	35637192
Pubmed	The Nuclear SUMO-Targeted Ubiquitin Quality Control Network Regulates the Dynamics of Cytoplasmic Stress Granules.	TARDBP DDX18 HNRNPM TOP2A	2.01e-05	65	85	4	32521226
Pubmed	A human MAP kinase interactome.	HNRNPM TNK2 KDM2A RAPGEF2 ZDHHC17 NEB GOLGA2 STAT1	2.58e-05	486	85	8	20936779
Pubmed	Defining the membrane proteome of NK cells.	CUL3 FADS1 ABI3 DDX18 HNRNPM TNK2 HSD11B1 ITGA4 CDC5L MED1 DDX41 POLR3A	2.67e-05	1168	85	12	19946888
Pubmed	SUMO-1 conjugation to human DNA topoisomerase II isozymes.	TOP2A TOP2B	3.53e-05	4	85	2	10862613
Pubmed	TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity.	FLT3 TRAF6	3.53e-05	4	85	2	35045331
Pubmed	Mechanistic insights of NAC1 nuclear export and its role in ovarian cancer resistance to docetaxel.	CUL3 CCNB1	3.53e-05	4	85	2	37019189
Pubmed	MicroRNA-370 carried by M2 macrophage-derived exosomes alleviates asthma progression through inhibiting the FGF1/MAPK/STAT1 axis.	MAP2K6 STAT1	3.53e-05	4	85	2	33994863
Pubmed	The Amino Acid Transporter Mct10/Tat1 Is Important to Maintain the TSH Receptor at Its Canonical Basolateral Localization and Assures Regular Turnover of Thyroid Follicle Cells in Male Mice.	TSHR CTSK	3.53e-05	4	85	2	34071318
Pubmed	ORP10, a cholesterol binding protein associated with microtubules, regulates apolipoprotein B-100 secretion.	OSBPL10 APOB	3.53e-05	4	85	2	22906437
Pubmed	Analysis of the MCMV resistome by ENU mutagenesis.	FLT3 STAT1	3.53e-05	4	85	2	16688530
Pubmed	FLT3/ ITD regulates leukaemia cell adhesion through α4β1 integrin and Pyk2 signalling.	FLT3 ITGA4	3.53e-05	4	85	2	21114537
Pubmed	Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY.	NPY4R2 NPY4R	3.53e-05	4	85	2	7592911
Pubmed	Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.	TRAF6 MAP2K6	3.53e-05	4	85	2	16313339
Pubmed	Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress.	TARDBP DDX18 HNRNPM CDC5L TOP2B	4.58e-05	159	85	5	22751105
Pubmed	A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape.	SMG1 POLR3B FADS1 VWA8 CDC5L PLD3 DDX41 STX10 TOP2A TOP2B POLR3A CCNB1 ARMC8	4.58e-05	1440	85	13	30833792
Pubmed	In-Depth In Vivo Crosslinking in Minutes by a Compact, Membrane-Permeable, and Alkynyl-Enrichable Crosslinker.	DOC2A EFCAB5 SMG1 TARDBP HNRNPM SCN9A APOB ZDHHC17 NEB DNAH8 TOP2A TOP2B CCDC158	4.65e-05	1442	85	13	35575683
Pubmed	A new sodium channel alpha-subunit gene (Scn9a) from Schwann cells maps to the Scn1a, Scn2a, Scn3a cluster of mouse chromosome 2.	SCN9A NEB	5.87e-05	5	85	2	8812438
Pubmed	Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY.	NPY4R2 NPY4R	5.87e-05	5	85	2	7493937
Pubmed	Velvet, a dominant Egfr mutation that causes wavy hair and defective eyelid development in mice.	FLT3 STAT1	5.87e-05	5	85	2	15020428
Pubmed	Huntingtin interacting proteins 14 and 14-like are required for chorioallantoic fusion during early placental development.	ITGA4 ZDHHC17	5.87e-05	5	85	2	25478910
Pubmed	Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.	TBC1D1 ROR1	5.87e-05	5	85	2	23153538
Pubmed	Histone deacetylase interacts directly with DNA topoisomerase II.	TOP2A TOP2B	5.87e-05	5	85	2	11062478
Pubmed	TNFR-associated factor 6 regulates TCR signaling via interaction with and modification of LAT adapter.	TRAF6 ZAP70	5.87e-05	5	85	2	23514740
Pubmed	BTB-ZF factors recruit the E3 ligase cullin 3 to regulate lymphoid effector programs.	CUL3 DDX18 TOP2A	6.03e-05	31	85	3	23086144
Pubmed	Mixed Lineage Leukemia 5 (MLL5) Protein Stability Is Cooperatively Regulated by O-GlcNac Transferase (OGT) and Ubiquitin Specific Protease 7 (USP7).	TRAF6 DDX18 TOP2A	6.03e-05	31	85	3	26678539
Interaction	CDC42 interactions	CUL3 ARHGEF40 PTPN14 FADS1 CCDC28A DDX18 UGCG PUS1 OSBPL10 TNK2 CDC5L STX10 PLEKHA7 RUFY1 ADCY9 TOP2B STAT1	1.94e-05	1323	82	17	int:CDC42
Interaction	SLFN11 interactions	CUL3 HNRNPM LAMA5 KDM2A CDC5L PLD3 DDX41 TOP2A VCL	2.20e-05	376	82	9	int:SLFN11
Interaction	GRWD1 interactions	CUL3 FLT3 DDX18 ROR1 HNRNPM CDC5L TOP2A TOP2B CCNB1	2.93e-05	390	82	9	int:GRWD1
Interaction	BRD3 interactions	POLR3B AKAP17A ABCA12 DDX18 MED1 DDX41 INO80D TOP2A TOP2B POLR3A	3.15e-05	494	82	10	int:BRD3
Interaction	HECTD1 interactions	CUL3 POLR3B PTPN14 AKAP17A DDX18 HNRNPM ERI1 CDC5L MED1 DDX41 TOP2A TOP2B POLR3A ARMC8	3.94e-05	984	82	14	int:HECTD1
Interaction	RHOH interactions	FADS1 CCDC28A PUS1 OSBPL10 STX10 PLEKHA7 RUFY1 ZAP70 ADCY9 TOP2B	4.26e-05	512	82	10	int:RHOH
Interaction	KMT2E interactions	TRAF6 TBC1D1 DDX18 TOP2A	4.69e-05	49	82	4	int:KMT2E
Interaction	ATG16L1 interactions	TARDBP ARHGEF40 PTPN14 TBC1D1 OSBPL10 TNK2 AKAP10 CCDC168 MED1 STX10 RUFY1 GOLGA2 TOP2A TOP2B STAT1	6.09e-05	1161	82	15	int:ATG16L1
Interaction	EMILIN1 interactions	TRAF6 ABI3 EMILIN2 PUS1 GOLGA2	6.32e-05	103	82	5	int:EMILIN1
GeneFamily	Topoisomerases	TOP2A TOP2B	1.78e-04	6	63	2	1050
Coexpression	GSE3982_CTRL_VS_LPS_4H_MAC_UP	ARHGEF40 ROR1 SLC25A14 ZDHHC17 RUFY1 TOP2B VCL	3.18e-06	200	82	7	M5367
Coexpression	RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_UP	ILRUN ARHGEF40 FADS1 TBC1D1 MATK TNK2 HSD11B1 CTSK STAT1	5.60e-06	411	82	9	M19971
Coexpression	CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_DN	ILRUN TARDBP FADS1 DDX18 HNRNPM PUS1 CDC5L DDX41 TOP2A VCL CCNB1	7.47e-06	669	82	11	M18635
Coexpression	GSE12845_IGD_POS_BLOOD_VS_NAIVE_TONSIL_BCELL_UP	CCDC28A DDX18 EMILIN2 PLD3 NEB VCL	3.44e-05	195	82	6	M3184
Coexpression	GSE22025_TGFB1_VS_TGFB1_AND_PROGESTERONE_TREATED_CD4_TCELL_UP	PTPN14 CCDC28A LAMA5 TNK2 PLD3 NOS1	3.85e-05	199	82	6	M8380
Coexpression	GSE41176_UNSTIM_VS_ANTI_IGM_STIM_BCELL_1H_DN	CCDC28A TBC1D1 SLC25A14 KCNAB2 STAT1 VCL	3.85e-05	199	82	6	M9913
Coexpression	GSE17721_LPS_VS_POLYIC_0.5H_BMDC_UP	ILRUN FLT3 KCNAB2 KCNN4 AKAP10 ERI1	3.96e-05	200	82	6	M3796
Coexpression	BUSSLINGER_GASTRIC_IMMUNE_CELLS	CUL3 SMG1 ABI3 TBC1D1 MATK KCNAB2 TNK2 KDM2A AKAP10 ITGA4 MED1 INO80D ZAP70 TOP2B STAT1	5.37e-05	1492	82	15	M40023
Coexpression	HE_LIM_SUN_FETAL_LUNG_C2_PRE_PDC_DC5_CELL	FLT3 MATK UGCG SCN9A PUS1 ZDHHC17 TOP2A POLR3A CCNB1	8.12e-05	578	82	9	M45744
ToppCell	mild-pDC\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	FLT3 ABCA12 UGCG SCN9A ZDHHC17 MAP2K6	2.14e-06	197	85	6	0cb00daa6943f7a7fb34a8fdf51188646af65686
ToppCell	mild-pDC\|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	FLT3 ABCA12 UGCG SCN9A ZDHHC17 MAP2K6	2.14e-06	197	85	6	15230a54fa5903dd728de1a0ad633bd2d2c7a04d
ToppCell	367C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_4\|367C / Donor, Lineage, Cell class and subclass (all cells)	ABI3 MATK TSHR ITGA4 ZAP70	1.23e-05	156	85	5	71f49db7d6da5533ecfcd4eacb50ecf1f30ee712
ToppCell	Children_(3_yrs)-Immune-dendritic_cell-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	FLT3 UGCG SCN9A ITGA4 MAP2K6	1.48e-05	162	85	5	86a0b9dabd150dc993bfc0f3344804de7f8e4042
ToppCell	droplet-Lung-18m-Hematologic-Lymphocytic_NK_ILC-natural_killer_cell-natural_killer\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	UGCG KCNAB2 HSD11B1 ITGA4 ZAP70	1.57e-05	164	85	5	c2cd4e4b88cc1b80a9494f59d31339007ff824c1
ToppCell	droplet-Spleen-SPLEEN-1m-Lymphocytic-NK_cell\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	AOX1 UGCG KCNAB2 HSD11B1 ZAP70	1.62e-05	165	85	5	8741df8066a44c841752a99ad306d26ea68f5344
ToppCell	B_cells-pDCs\|World / Immune cells in Kidney/Urine in Lupus Nephritis	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	1.76e-05	168	85	5	dc8f94424f60ab56facdcffa969e7f3466ee1b6e
ToppCell	facs-Heart-LV-18m-Lymphocytic-T_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCN9A KCNAB2 KCNN4 DNAH8 ZAP70	1.87e-05	170	85	5	71e5e27c3c4e6cc8dc9b063bd51c21c049f54416
ToppCell	facs-Heart-LV-18m-Lymphocytic-T_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCN9A KCNAB2 KCNN4 DNAH8 ZAP70	1.87e-05	170	85	5	255bbbd00d0e17510c5a8c5faa43ed90d887a9de
ToppCell	5'-Adult-LymphNode-Hematopoietic-T_cells-CX3CR1+_CD8_Tmem\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ABI3 MATK KCNAB2 ITGA4 ZAP70	2.14e-05	175	85	5	dddeced0cfcf71d03bcf349983908b3bfb0ab51d
ToppCell	PND07-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_T-Treg-Treg_prolif\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	KCNAB2 KCNN4 ZAP70 TOP2A CCNB1	2.26e-05	177	85	5	f10f77130dbb2c0ad1b436ceb4fb1deac2b0267c
ToppCell	facs-Marrow-T_cells-18m-Lymphocytic-BM_CD4_T_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KCNN4 PLD3 NEB ZAP70 STAT1	2.33e-05	178	85	5	888add8935ef3aef9b6693c5698e9d1842e66337
ToppCell	facs-Marrow-T_cells-18m-Lymphocytic-CD4-positive,_alpha-beta_T_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KCNN4 PLD3 NEB ZAP70 STAT1	2.33e-05	178	85	5	43eda32af2e5e28a92421612d0a4c21e5427a772
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ABCA12 SCN9A APOB NEB DNAH9	2.73e-05	184	85	5	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ABCA12 SCN9A APOB NEB DNAH9	2.73e-05	184	85	5	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ABCA12 SCN9A APOB NEB DNAH9	2.73e-05	184	85	5	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	BAL-Mild-Myeloid-pDC-pDC\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	2.80e-05	185	85	5	f4588468e8654363f48adbe427dff10f16f1c7fe
ToppCell	BAL-Mild-Myeloid-pDC-pDC-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	2.80e-05	185	85	5	3cb816fc9541c04b4436e21d984216cfbbacff98
ToppCell	ICU-NoSEP-Myeloid-pDC\|ICU-NoSEP / Disease, Lineage and Cell Type	KANK1 UGCG SCN9A ZDHHC17 MAP2K6	2.80e-05	185	85	5	7564a47df4a4e3af30d40aa0f48bd9d9c82358ae
ToppCell	BAL-Mild-Myeloid-pDC\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	2.80e-05	185	85	5	c2e70405969616c28fb6379ee318e17bbcef7b49
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L3-4_PVALB_HOMER3\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	FLT3 ROR1 SCN9A TSHR PLEKHA7	2.87e-05	186	85	5	948815663c212c4311329d503b5991cbbbff9808
ToppCell	BAL-Mild-Myeloid-pDC-pDC\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	2.87e-05	186	85	5	b031f4e6867b6200b85f43276a34749bf5f4603f
ToppCell	BAL-Mild-Myeloid-pDC\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	2.87e-05	186	85	5	d2fbf53aac905c9896272ec5c2db28ee1a60f4be
ToppCell	BAL-Mild-Myeloid-pDC-pDC-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	2.87e-05	186	85	5	79aedd5aed72509a4925e9f6cb43bc0c798c86f5
ToppCell	Mild_COVID-19-Myeloid-pDC\|Mild_COVID-19 / Disease group,lineage and cell class （2021.01.30）	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	2.95e-05	187	85	5	99c3c4a7b9179dce7982dc6516d561c952abc80e
ToppCell	PBMC-Mild-Myeloid-pDC-pDC\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	3.02e-05	188	85	5	89411c4db3df5e1dc36cf8af4ffcc0abbecbe4df
ToppCell	PBMC-Mild-Myeloid-pDC\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	3.02e-05	188	85	5	de6a270b6e4fe09c39a52c296632d86ada98465b
ToppCell	COVID-19_Severe-pDC\|World / disease group, cell group and cell class	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	3.02e-05	188	85	5	4c8e328b8206120708b05ea3c5865a0200dc5c4e
ToppCell	PBMC-Mild-Myeloid-pDC-pDC-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	3.02e-05	188	85	5	879054b780378ae05be68e597c77c931bf0ade03
ToppCell	PBMC-Mild-Myeloid-pDC\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	3.10e-05	189	85	5	209cae68d78c8f72479b169e27c3ff7e143adece
ToppCell	PBMC-Mild-Myeloid-pDC-pDC-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	3.10e-05	189	85	5	a9ad1fb12304541f909dd0eeac9b9eb28c31fd41
ToppCell	COVID-19_Mild-Myeloid-pDC\|COVID-19_Mild / Disease group, lineage and cell class	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	3.10e-05	189	85	5	c6cfd6aa21c19f2c62d80218bbc924e14e82aada
ToppCell	PBMC-Mild-Myeloid-pDC-pDC\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	3.10e-05	189	85	5	98ca646231fbd5f29827c2dd31ac4503026bad7d
ToppCell	COVID-19_Moderate-pDC\|COVID-19_Moderate / disease group, cell group and cell class	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	3.26e-05	191	85	5	9d0ffa65c547e20b4076fd97776d7738cbd453ec
ToppCell	Adult-Immune-monocyte-D175\|Adult / Lineage, Cell type, age group and donor	ABI3 TBC1D1 EMILIN2 KCNN4 ITGA4	3.26e-05	191	85	5	cbebb4d9550fdcd606cb3685ac9546c6b73fd422
ToppCell	P07-Mesenchymal-developing_mesenchymal_cell-mesenchymal_myogenic_precursor_(Axin2+)\|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	TBC1D1 EGFLAM HSD11B1 ITGA4 RAPGEF2	3.26e-05	191	85	5	2ad717b59215ad8d933e9637d363b65d7298e5d4
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Vascular-Mural_cell-SMC_prolif-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	EGFLAM ITGA4 CTSK TOP2A VCL	3.51e-05	194	85	5	78dcb9d48259afabe73b41c5508a73a8d62339a4
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-DC-pDC-Z\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	3.60e-05	195	85	5	06051de72b5c1e0d483a28b14dabd247dfca0ed9
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-DC-pDC\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	3.60e-05	195	85	5	3aa44633c72658545aa2b35bf9d532c62f36a451
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_T/NK-CD8-positive,_alpha-beta_T_cell-CD8_T_cells-CD8_T_cells_L.1.1.0.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ABI3 MATK ITGA4 ZAP70 STAT1	3.78e-05	197	85	5	0e93800d5df652a9c691c66a3f75a2e8979aed8e
ToppCell	Parenchyma_Control_(B.)-Immune-TX-MoAM-4\|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type	TRAF6 MATK MTMR8 SCN9A KCNN4	3.78e-05	197	85	5	dc1c55e3aacc9d60d0f111c2f20f150ca296f011
ToppCell	343B-Myeloid-Dendritic\|Myeloid / Donor, Lineage, Cell class and subclass (all cells)	FLT3 UGCG KCNN4 ITGA4 TOP2A	3.78e-05	197	85	5	b340d6f041231e5c69140895aaa1e8d28bafb998
ToppCell	Parenchymal-NucSeq\|Parenchymal / Cell types per location group and 10X technology with lineage, and cell group designations	KANK1 ROR1 RAPGEF2 PLEKHA7 ADCY9	3.87e-05	198	85	5	1996373bdccc55aac347d349bd22f6aad6d0c668
ToppCell	Macrophages-IPF_03\|World / lung cells shred on cell class, cell subclass, sample id	MATK EMILIN2 HSD11B1 CTSK STAT1	3.87e-05	198	85	5	8517386a2f0d14c7d5fc6283e4e16b94d7c5732a
ToppCell	Tracheal-NucSeq-Immune_Lymphocytic-NK-ILC-T_NK-NK\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	MATK KCNAB2 CCDC168 ITGA4 ZAP70	3.96e-05	199	85	5	598937913fe1f12d741fa49e23ae195a7be5cbe3
ToppCell	MS-Multiple_Sclerosis-Myeloid-pDC\|Multiple_Sclerosis / Disease, condition lineage and cell class	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	3.96e-05	199	85	5	c10c8c9322cad4996e4aa11a8680e3d781644ace
ToppCell	Sepsis-URO-Myeloid-pDC\|URO / Disease, condition lineage and cell class	KANK1 UGCG SCN9A ZDHHC17 MAP2K6	3.96e-05	199	85	5	1dc96a1cc313fa175fe50f0df606baa84ea5970b
ToppCell	Sepsis-ICU-NoSEP-Myeloid-pDC\|ICU-NoSEP / Disease, condition lineage and cell class	KANK1 UGCG SCN9A ZDHHC17 MAP2K6	3.96e-05	199	85	5	a199e67438eeed903d0996605591ec54400fdd66
ToppCell	COVID-19-COVID-19_Mild-Myeloid-pDC\|COVID-19_Mild / Disease, condition lineage and cell class	FLT3 UGCG SCN9A ZDHHC17 MAP2K6	3.96e-05	199	85	5	9de61e5189d907cc969ac3043d68204f70acc0bf
ToppCell	TCGA-Stomach-Primary_Tumor\|TCGA-Stomach / Sample_Type by Project: Shred V9	TARDBP DDX18 HNRNPM PUS1 TOP2A	3.96e-05	199	85	5	38f1f612b29feb868322999ceeda78e52447ec4f
ToppCell	TCGA-Stomach-Primary_Tumor-Stomach_Adenocarcinoma\|TCGA-Stomach / Sample_Type by Project: Shred V9	TARDBP DDX18 HNRNPM PUS1 TOP2A	3.96e-05	199	85	5	b10698aee2e6c17bc559eb4f723024141f914b90
ToppCell	Parenchymal-NucSeq-Immune_Lymphocytic-NK-ILC-T_NK-NK\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	ABI3 MATK KCNAB2 ITGA4 ZAP70	4.06e-05	200	85	5	7d90fcb5dfc4c9d562c93b0f9293ed12b5f4f404
ToppCell	Parenchymal-NucSeq-Immune_Lymphocytic-NK-ILC\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	ABI3 MATK KCNAB2 ITGA4 ZAP70	4.06e-05	200	85	5	d2422aaf807010194994db97142b9fd2e807312d
ToppCell	Parenchymal-NucSeq-Immune_Lymphocytic-NK-ILC-T_NK\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	ABI3 MATK KCNAB2 ITGA4 ZAP70	4.06e-05	200	85	5	1d2ee63010b7b8b38bea7d3b30eebfbcdd18b967
ToppCell	Neuronal-Inhibitory-iB\|Neuronal / cells hierarchy compared to all cells using T-Statistic	FLT3 ARHGEF40 ROR1 SCN9A NOS1	4.06e-05	200	85	5	45ddc5ef2caa87ada88327b63ba9b150a6bb3aa5
ToppCell	(05)_Ciliated-(3)_72hpi\|(05)_Ciliated / shred by cell type and Timepoint	CPT1B DNAH8 TOP2A CCNB1	6.53e-05	113	85	4	eaa5bc8f8183b353ee1e7618e99220eb3684cd60
ToppCell	LPS-antiTNF-Myeloid-Dendritic_cells-Monocytes-Macrophages\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	FLT3 FAT2 TRPA1 EMILIN2	1.06e-04	128	85	4	cfc73cb803ba50a4a8709e19e70e1e399118c849
ToppCell	Parenchymal-10x3prime_v2-Immune_Myeloid-Dendritic_cell-DC_plasmacytoid\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	FLT3 SCN9A TNK2 FAAP100	1.26e-04	134	85	4	0e3f37ef041b751ed45060b5ce39385a2731370b
ToppCell	droplet-Heart-nan-3m-Hematologic-nan\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FLT3 KCNN4 ITGA4 ZAP70	1.50e-04	140	85	4	ab90f6f30d89761687f8836e3d327d143ce49ed4
ToppCell	LPS_only-Myeloid-Dendritic_cells\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	FLT3 EMILIN2 ITGA4 MAP2K6	1.85e-04	148	85	4	cb9365663f9cba35d47b5dd9079f42e88b70d915
ToppCell	droplet-Liver-LIVER_HEPATOCYTES-30m-Myeloid-macrophage/monocyte\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FLT3 MATK ITGA4 CCDC158	1.90e-04	149	85	4	48fca6ae33d7722c024b43ce04f4dbce7b6b424b
ToppCell	droplet-Liver-LIVER_HEPATOCYTES-30m-Myeloid-myeloid_leukocyte\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FLT3 MATK ITGA4 RUFY1	2.05e-04	152	85	4	7e686721b95c837f2b0d5116927c8ecacef055ee
ToppCell	facs-Brain_Myeloid-Cortex-3m-Myeloid-macrophage\|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TCEA3 EMILIN2 HSD11B1 ITGA4	2.10e-04	153	85	4	0ef7c45cdd854c79e527006034029767f8e108b2
ToppCell	343B-Lymphocytic-NK_cells-NK_cell_B\|343B / Donor, Lineage, Cell class and subclass (all cells)	ABI3 MATK ITGA4 ZAP70	2.15e-04	154	85	4	886e7cd01cb48ca3e97debeea2b1f100b09d47e6
ToppCell	COVID-19-Heart-CM_5_(RYR2-)\|Heart / Disease (COVID-19 only), tissue and cell type	TCEA3 NEB MAP2K6 NOS1	2.21e-04	155	85	4	d7e26696fd9c0a759524f331243db43059b33ed9
ToppCell	facs-Brain_Myeloid-Cortex_-18m-Myeloid-macrophage\|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TCEA3 EMILIN2 ITGA4 CCDC158	2.26e-04	156	85	4	2ba838bc864c2c1767bcab7bb4d790af96b91387
ToppCell	PND07-28-samps-Mesenchymal-Mesothelial\|PND07-28-samps / Age Group, Lineage, Cell class and subclass	CHST4 OSBPL10 TSHR ADCY9	2.26e-04	156	85	4	574f761962a7dd3308bd41fc529dd3ea1b8625f8
ToppCell	PND07-28-samps-Mesenchymal-Mesothelial-Mesothelial\|PND07-28-samps / Age Group, Lineage, Cell class and subclass	CHST4 OSBPL10 TSHR ADCY9	2.26e-04	156	85	4	605d95a900e1443d3f6aae163ef2e893d3293203
ToppCell	356C-Myeloid-Dendritic-pDC\|356C / Donor, Lineage, Cell class and subclass (all cells)	SMG1 FLT3 UGCG ZDHHC17	2.26e-04	156	85	4	d9d87368e43b24952e70f31f38425e15b716ff5b
ToppCell	E18.5-Immune-Immune_Myeloid-Monocytic-Macrophage-iMON-iMON_G2M\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	KCNAB2 EMILIN2 ITGA4 TOP2A	2.32e-04	157	85	4	904cd98ae85ed6459e0663f077ac462842bf12df
ToppCell	facs-Lung-24m-Hematologic-Lymphocytic_NK_ILC-natural_killer_cell-natural_killer\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	POLR3B UGCG PLD3 ZAP70	2.32e-04	157	85	4	34eb1cbdb023d3e23b2e1695c9c327c21ef1c870
ToppCell	facs-Lung-24m-Hematologic-Lymphocytic_NK_ILC-natural_killer_cell\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	POLR3B UGCG PLD3 ZAP70	2.32e-04	157	85	4	fc0c222124f59c94d60335f849554eaa4062f8c7
ToppCell	facs-Lung-24m-Hematologic-Lymphocytic_NK_ILC\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	POLR3B UGCG PLD3 ZAP70	2.32e-04	157	85	4	40b08ace1d9ea7951886f5fed76ac57e9175436b
ToppCell	facs-Marrow-T_cells-18m-Lymphocytic-NK_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	UGCG HSD11B1 PLD3 ZAP70	2.38e-04	158	85	4	9f0987eaf1766aadb5714b68df7a5d310ea5a57a
ToppCell	facs-Marrow-T_cells-18m-Lymphocytic-NK_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	UGCG HSD11B1 PLD3 ZAP70	2.43e-04	159	85	4	94bc6ab248a8f02ccbc0facd24e0c7e9fda687d2
ToppCell	LPS-antiTNF-Myeloid-Monocytes,_Macrophages-Neutrophils\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MATK EMILIN2 HSD11B1 ERI1	2.49e-04	160	85	4	5d8d97c3da5837ba5fe743d2f8438f5cb7cea64b
ToppCell	COVID_non-vent-Lymphocytic-Dendritic-pDC\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	FLT3 UGCG SCN9A ZDHHC17	2.49e-04	160	85	4	61f4cb4eb4313d8318aadbb99595a6cb7fd919f7
ToppCell	COVID_non-vent-Lymphocytic-Dendritic\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	FLT3 UGCG SCN9A ZDHHC17	2.49e-04	160	85	4	34b4f710cfcb6ec370b8b074f3cbfe272f392cec
ToppCell	droplet-Lung-18m-Hematologic-lymphocytic-mature_NK_T_cell-mature_NK_T_cell_l44\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	UGCG TNK2 ITGA4 ZAP70	2.49e-04	160	85	4	6b0faaa371650563f585722f5b2fb319e124ec38
ToppCell	356C-Lymphocytic-NK_cells-NK_cell_D\|356C / Donor, Lineage, Cell class and subclass (all cells)	ABI3 MATK MTMR8 ZAP70	2.55e-04	161	85	4	8fe9fde47e691c443d13d8616c654fbae2d5675c
ToppCell	LAM-Lymphoid-pDC\|LAM / Condition, Lineage and Cell class	UGCG SCN9A ZDHHC17 MAP2K6	2.55e-04	161	85	4	bb5b44713e4da4406cdaa79dcf2aa9f97e3cf75a
ToppCell	droplet-Lung-nan-18m-Lymphocytic-Natural_Killer\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	UGCG KCNAB2 HSD11B1 ZAP70	2.61e-04	162	85	4	66069146e2666d13c594bd76247893354a697c5d
ToppCell	droplet-Lung-nan-3m-Lymphocytic-NK_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	UGCG KCNAB2 HSD11B1 ZAP70	2.61e-04	162	85	4	4b490989005bb03d4e7bbea01580f8548eff150f
ToppCell	droplet-Lung-nan-3m-Lymphocytic-Natural_Killer\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	UGCG KCNAB2 HSD11B1 ZAP70	2.61e-04	162	85	4	e4a09bf1a51710f6c57e6e01edf8b4619459d96d
ToppCell	droplet-Liver-LIVER_HEP-30m-Myeloid-macrophage/monocyte\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DOC2A FLT3 ITGA4 STAT1	2.61e-04	162	85	4	93bd29c52846c3156b8b0d2e39c552373efdfe93
ToppCell	3'-Airway_Nasal-Immune_Lymphocytic-Lymphocytic_T/NK-natural_killer_cell-NK_cells\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MATK CCDC168 NEB ZAP70	2.68e-04	163	85	4	e6213900f56257fe38ac7852351bea0340294be0
ToppCell	3'-Airway_Nasal-Immune_Lymphocytic-Lymphocytic_T/NK-natural_killer_cell\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MATK CCDC168 NEB ZAP70	2.68e-04	163	85	4	ed7319185c1ec384444309bb8be95691a0c2091c
ToppCell	droplet-Lung-nan-18m-Lymphocytic-NK_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	UGCG KCNAB2 HSD11B1 ZAP70	2.68e-04	163	85	4	801163c05f8fdacaebd0cb9b4c92741276bfa3e3
ToppCell	droplet-Spleen-nan-3m-Lymphocytic-NK_cell\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	UGCG HSD11B1 ITGA4 ZAP70	2.68e-04	163	85	4	2e1c1193c04620cc187b1567dfba025beef1e4e1
ToppCell	3'-Airway_Nasal-Immune_Lymphocytic-Lymphocytic_T/NK-natural_killer_cell-NK_cells-NK_cells_L.1.3.0.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MATK CCDC168 NEB ZAP70	2.68e-04	163	85	4	ef35d7ff09aa364734fea7fdaab6260c0a3fbf09
ToppCell	facs-Marrow-T-cells-3m-Lymphocytic-NK_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	UGCG HSD11B1 PLD3 ZAP70	2.74e-04	164	85	4	9fed5df40f50bde35db8bf89c291cbdc0e104112
ToppCell	facs-Marrow-T-cells-3m-Lymphocytic-NK_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	UGCG HSD11B1 PLD3 ZAP70	2.74e-04	164	85	4	e712d6b89461f741dbd773ba9a27ecaddf97cbaa
ToppCell	facs-BAT-Fat-3m-Lymphocytic-NK_cell\|BAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	UGCG KCNAB2 HSD11B1 ZAP70	2.74e-04	164	85	4	cbdb7e893cb3959b9920c0c7c535ace03a5f4986
ToppCell	droplet-Lung-LUNG-30m-Lymphocytic-Natural_Killer\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	UGCG KCNAB2 HSD11B1 ZAP70	2.74e-04	164	85	4	e9e5a1462d8ed60b2e5bf603c8c47eb85bce83d5
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Immune-Lymphocytic_T/NK-Natural_Killer_Cell_/_Natural_Killer_T_Cell-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MATK KCNAB2 ITGA4 ZAP70	2.74e-04	164	85	4	649e42d9cfdec2f7771d1e938b516e46e7d07078
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Immune-Lymphocytic_T/NK-Natural_Killer_Cell_/_Natural_Killer_T_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MATK KCNAB2 ITGA4 ZAP70	2.74e-04	164	85	4	ba85f7b21ae34e285d286ada24715885ca6329f7
ToppCell	droplet-Lung-18m-Hematologic-Lymphocytic_NK_ILC-natural_killer_cell\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	UGCG KCNAB2 HSD11B1 ZAP70	2.74e-04	164	85	4	d4d08353c7322f97ea07dd583b08661d635fff20
ToppCell	droplet-Lung-18m-Hematologic-Lymphocytic_NK_ILC\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	UGCG KCNAB2 HSD11B1 ZAP70	2.80e-04	165	85	4	88745bf7ecb0f7fc93077cea20171d40535dd56b
ToppCell	facs-Brain_Myeloid-Hippocampus-24m-Myeloid-macrophage\|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KCNAB2 EMILIN2 HSD11B1 ITGA4	2.80e-04	165	85	4	ab6ed7e30096c418e7be2d5eec33feeddd1387d9
ToppCell	facs-Lung-nan-3m-Myeloid-myeloid_dendritic_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FLT3 VWA8 CCDC28A MATK	2.87e-04	166	85	4	5c132f505dc5f699c87913f140344fc9f8e7e0f5
Drug	genistein	TRPA1 MATK HNRNPM LAMA5 APOB ITGA4 PLD3 DDX41 STX10 MAP2K6 NOS1 ZAP70 TOP2B STAT1 VCL CCNB1	1.99e-06	1117	82	16	CID005280961
Drug	AC1L1G9T	MATK ITGA4 PLD3 DDX41 MAP2K6 NOS1 ZAP70 TOP2B STAT1 VCL	3.52e-06	433	82	10	CID000003591
Drug	19-noraldosterone	UGCG HSD11B1 NOS1	3.72e-06	9	82	3	CID000127113
Drug	17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A	AOX1 PUS1 KDM2A PLD3 CTSK ADCY9 ARMC8	6.27e-06	193	82	7	6985_DN
Drug	Meglumine [6284-40-8]; Down 200; 20.4uM; MCF7; HT_HG-U133A	ILRUN KCNN4 PLD3 CPT1B NEB GOLGA2 STAT1	7.17e-06	197	82	7	5285_DN
Drug	Amprolium hydrochloride [137-88-2]; Down 200; 12.6uM; MCF7; HT_HG-U133A	ILRUN MATK AOX1 UGCG KCNN4 AKAP10 MED1	7.41e-06	198	82	7	1479_DN
Drug	daidzein	MATK APOB MAP2K6 NOS1 TOP2B STAT1	1.26e-05	142	82	6	CID005281708
Drug	Dexrazoxane	TOP2A TOP2B	1.28e-05	2	82	2	DB00380
Drug	F14512	TOP2A TOP2B	1.28e-05	2	82	2	ctd:C534191
Drug	Daunorubicin	TOP2A TOP2B	1.28e-05	2	82	2	DB00694
Drug	NSC618487	FLT3 MATK TNK2 APOB PLD3 MAP2K6 NOS1 ZAP70 ADCY9 TOP2B STAT1 VCL CCNB1	2.74e-05	933	82	13	CID000005279
Drug	XK469	AOX1 TOP2B CCNB1	2.95e-05	17	82	3	CID000148183
Drug	phorbol acetate myristate	CUL3 POLR3B TRPA1 MATK TNK2 APOB TSHR ITGA4 PLD3 CPT1B STX10 MAP2K6 NOS1 ZAP70 ADCY9 VCL	3.34e-05	1399	82	16	CID000004792
Drug	nonylphenol	TARDBP TRAF6 DDX18 APOB TSHR HSD11B1 MAP2K6 STAT1 VCL	6.20e-05	485	82	9	ctd:C025256
Drug	Pyrimethamine [58-14-0]; Down 200; 16uM; HL60; HG-U133A	KCNN4 AKAP10 RAPGEF2 INO80D TOP2A CCNB1	6.46e-05	190	82	6	1974_DN
Drug	a-X-d	LAMA5 APOB VCL	6.60e-05	22	82	3	CID011987862
Drug	verapamil	TRPA1 ABCA12 SCN9A KCNAB2 KCNN4 APOB NOS1 ADCY9 TOP2B	6.70e-05	490	82	9	CID000002520
Drug	nordihydroguaiaretic acid; Up 200; 1uM; MCF7; HT_HG-U133A_EA	TRAF6 FADS1 KCNN4 CDC5L RAPGEF2 PLD3	7.24e-05	194	82	6	1061_UP
Drug	acridine-4-carboxamide	AOX1 TOP2B	7.65e-05	4	82	2	CID003025721
Drug	NSC 601316	AOX1 TOP2B	7.65e-05	4	82	2	CID000107805
Drug	XK 469	AOX1 CCNB1	7.65e-05	4	82	2	ctd:C118180
Drug	Gossypol [303-45-7]; Down 200; 7.8uM; MCF7; HT_HG-U133A	CUL3 AOX1 KCNAB2 CDC5L ADCY9 ARMC8	7.67e-05	196	82	6	6058_DN
Drug	wortmannin from Penicillium funiculosum; Down 200; 0.01uM; MCF7; HT_HG-U133A	DOC2A MED1 RAPGEF2 NEB INO80D ADCY9	7.67e-05	196	82	6	5240_DN
Drug	Racecadotril [81110-73-8]; Down 200; 10.4uM; MCF7; HT_HG-U133A	ILRUN CUL3 KCNN4 AKAP10 PLD3 CTSK	7.89e-05	197	82	6	6231_DN
Drug	Proglumide [6620-60-6]; Down 200; 12uM; HL60; HT_HG-U133A	ILRUN VWA8 KDM2A AKAP10 HS1BP3 STAT1	7.89e-05	197	82	6	2363_DN
Drug	Rilmenidine hemifumarate [54187-04-1]; Down 200; 8.4uM; MCF7; HT_HG-U133A	TRAF6 CCDC28A SLC25A14 HS1BP3 FAAP100 GOLGA2	8.11e-05	198	82	6	5532_DN
Drug	Vitexin [3681-93-4]; Down 200; 9.2uM; HL60; HT_HG-U133A	KDM2A HS1BP3 NEB NOS1 INO80D GOLGA2	8.11e-05	198	82	6	2155_DN
Drug	Adenosine 5'-monophosphate monohydrate [18422-05-4]; Up 200; 11uM; MCF7; HT_HG-U133A	NPY4R ABCA12 TBC1D1 CDC5L MAP2K6 NOS1	8.34e-05	199	82	6	5359_UP
Drug	Gentamicine sulfate [1405-41-0]; Down 200; 2.6uM; PC3; HT_HG-U133A	SLC25A14 KCNAB2 CPT1B NEB INO80D STAT1	8.57e-05	200	82	6	5883_DN
Disease	acute myeloid leukemia (implicated_via_orthology)	FLT3 TOP2A TOP2B	4.64e-06	12	83	3	DOID:9119 (implicated_via_orthology)
Disease	LEUKODYSTROPHY, HYPOMYELINATING, 7, WITH OR WITHOUT OLIGODONTIA AND/OR HYPOGONADOTROPIC HYPOGONADISM	POLR3B POLR3A	7.82e-06	2	83	2	607694
Disease	Leukoencephalopathy-ataxia-hypodontia-hypomyelination syndrome	POLR3B POLR3A	7.82e-06	2	83	2	cv:C2676243
Disease	B cell deficiency (implicated_via_orthology)	TOP2A TOP2B	7.82e-06	2	83	2	DOID:2115 (implicated_via_orthology)
Disease	hypomyelinating leukodystrophy (implicated_via_orthology)	POLR3B POLR3A	2.34e-05	3	83	2	DOID:0060786 (implicated_via_orthology)
Disease	Leukodystrophy, Hypomyelinating, with Hypodontia and Hypogonadotropic Hypogonadism	POLR3B POLR3A	2.34e-05	3	83	2	C2676243
Disease	POLR3-related leukodystrophy	POLR3B POLR3A	2.34e-05	3	83	2	cv:C5679947
Disease	thyroid stimulating hormone measurement	KANK1 PTPN14 TSHR ERI1 NEB MAP2K6 ADCY9	3.60e-05	323	83	7	EFO_0004748
Disease	Ovarian Mucinous Adenocarcinoma	MATK ROR1 TNK2	9.11e-05	31	83	3	C1335167
Disease	Early Childhood Epilepsy, Myoclonic	SCN9A RAPGEF2	2.16e-04	8	83	2	C0393695
Disease	Idiopathic Myoclonic Epilepsy	SCN9A RAPGEF2	2.16e-04	8	83	2	C0338478
Disease	Symptomatic Myoclonic Epilepsy	SCN9A RAPGEF2	2.16e-04	8	83	2	C0338479
Disease	Benign Infantile Myoclonic Epilepsy	SCN9A RAPGEF2	2.16e-04	8	83	2	C0751120
Disease	Myoclonic Encephalopathy	SCN9A RAPGEF2	2.16e-04	8	83	2	C0438414
Disease	Acute erythroleukemia - M6a subtype	FLT3 DDX41	2.16e-04	8	83	2	C2930975
Disease	Acute myeloid leukemia FAB-M6	FLT3 DDX41	2.16e-04	8	83	2	C2930976
Disease	Acute erythroleukemia - M6b subtype	FLT3 DDX41	2.16e-04	8	83	2	C2930977
Disease	Acute erythroleukemia	FLT3 DDX41	2.16e-04	8	83	2	C2930974
Disease	Myoclonic Absence Epilepsy	SCN9A RAPGEF2	2.16e-04	8	83	2	C0393703
Disease	Myoclonic Epilepsy	SCN9A RAPGEF2	2.78e-04	9	83	2	C0014550
Disease	Epilepsy, Myoclonic, Infantile	SCN9A RAPGEF2	3.47e-04	10	83	2	C0917800
Disease	Tourette syndrome	FLT3 POLR3B TSHR	3.82e-04	50	83	3	EFO_0004895
Disease	Myoclonic Astatic Epilepsy	SCN9A RAPGEF2	4.23e-04	11	83	2	C0393702
Disease	vascular endothelial growth factor measurement	VWA8 ROR1 CDC5L	5.34e-04	56	83	3	EFO_0004762
Disease	Infantile Severe Myoclonic Epilepsy	SCN9A RAPGEF2	5.98e-04	13	83	2	C0751122
Disease	Malignant neoplasm of breast	PTPN14 DDX18 ROR1 MTMR8 PUS1 HSD11B1 RUFY1 DNAH9 TOP2A STAT1	8.58e-04	1074	83	10	C0006142
Disease	low density lipoprotein cholesterol measurement, physical activity	FADS1 DDX18 APOB	8.64e-04	66	83	3	EFO_0003940, EFO_0004611
Disease	granulocyte percentage of myeloid white cells	FLT3 FADS1 KCNN4 ITGA4 CDC5L	9.71e-04	268	83	5	EFO_0007997
Disease	total cholesterol measurement, hematocrit, stroke, ventricular rate measurement, body mass index, atrial fibrillation, high density lipoprotein cholesterol measurement, coronary artery disease, diastolic blood pressure, triglyceride measurement, systolic blood pressure, heart failure, diabetes mellitus, glucose measurement, mortality, cancer	FADS1 ABCA12 APOB	9.84e-04	69	83	3	EFO_0000275, EFO_0000400, EFO_0000712, EFO_0001645, EFO_0003144, EFO_0004340, EFO_0004348, EFO_0004352, EFO_0004468, EFO_0004530, EFO_0004574, EFO_0004612, EFO_0006335, EFO_0006336, EFO_0007928, MONDO_0004992
Disease	phosphatidylcholine 40:6 measurement	RAPGEF2 DNAH9	1.03e-03	17	83	2	EFO_0010389
Disease	monocyte percentage of leukocytes	FLT3 FADS1 TBC1D1 KCNN4 ITGA4 CDC5L RUFY1 ADCY9	1.05e-03	731	83	8	EFO_0007989
Disease	sodium-coupled monocarboxylate transporter 1 measurement	FADS1 APOB	1.30e-03	19	83	2	EFO_0802076
Disease	lymphocyte:monocyte ratio	FLT3 TBC1D1 KCNN4 ITGA4 CDC5L	1.34e-03	288	83	5	EFO_0600088
Disease	sex interaction measurement, cerebral amyloid angiopathy	HS1BP3 ADCY9	1.59e-03	21	83	2	EFO_0006790, EFO_0008343
Disease	proprotein convertase subtilisin/kexin type 9 measurement	FADS1 APOB	1.74e-03	22	83	2	EFO_0009312
Disease	heel bone mineral density, urate measurement	NPY4R2 NPY4R VWA8 PUS1	1.76e-03	182	83	4	EFO_0004531, EFO_0009270
Disease	creatinine measurement	TCEA3 PTPN14 FADS1 LAMA5 TNK2 MED1 NEB PLEKHA7 CCDC158	1.92e-03	995	83	9	EFO_0004518
Disease	nephrotic syndrome (biomarker_via_orthology)	APOB NOS1	2.07e-03	24	83	2	DOID:1184 (biomarker_via_orthology)
Disease	level of Sterol ester (27:1/18:2) in blood serum	FADS1 APOB	2.43e-03	26	83	2	OBA_2045194
Disease	level of Sterol ester (27:1/16:0) in blood serum	FADS1 APOB	2.43e-03	26	83	2	OBA_2045191
Disease	Nephrotic Syndrome	KANK1 LAMA5	2.62e-03	27	83	2	C0027726
Disease	apolipoprotein B measurement	ILRUN FADS1 CHST4 DDX18 APOB HS1BP3 MAP2K6	2.66e-03	663	83	7	EFO_0004615
Disease	apolipoprotein A 1 measurement	ILRUN TCEA3 FLT3 FADS1 HNRNPM APOB TSHR MAP2K6	2.66e-03	848	83	8	EFO_0004614
Disease	low density lipoprotein cholesterol measurement, alcohol consumption measurement	ILRUN FADS1 APOB	2.77e-03	99	83	3	EFO_0004611, EFO_0007878

Protein segments in the cluster

Peptide	Gene	Start	Entry
NHLGDMTSEEVVQKM	CTSK	76	P43235
LRINEKMHAGQLMSV	ERI1	316	Q8IV48
LVQEMEVVKQGMSHG	CDC5L	636	Q99459
SIHERIQMDSMVIKG	EGFLAM	191	Q63HQ2
AHNKELRVQQMVSMG	ARHGEF40	1376	Q8TER5
VIHEMSAQTGKFERM	C1orf141	336	Q5JVX7
EMARAGTHQVSMETQ	AKAP10	251	O43572
TDLHTVRKNMGVCMQ	ABCA12	1411	Q86UK0
ETAMKAVSGIVHMQA	HSD11B1	221	P28845
KIQMAMVHGVTTEEC	TNK2	961	Q07912
EMGQGVHTKMIQVVS	AOX1	1046	Q06278
VEARVSTLGQMVNMH	ABI3	86	Q9P2A4
QVRMVDMQKLTHGVL	PLD3	186	Q8IV08
ETAVMTKMQHENLVR	MATK	276	P42679
LREQVNSMVDISKMH	KCNN4	361	O15554
RAGHMKQVNVVLVVM	NPY4R	256	P50391
MGIENIHVMRSSLQK	MTMR8	271	Q96EF0
EHARRAMQKVMATTG	HNRNPM	151	P52272
QRHIMGSQVEMEIVK	LMOD2	306	Q6P5Q4
CSIEQMEHVRGMQEK	CCDC28A	201	Q8IWP9
SAKEMEHSVGVQMRS	FAT2	3706	Q9NYQ8
KRQVVETMGLFHDMV	DNAH8	3006	Q96JB1
QTRDQMVGSHMDLVD	KANK1	521	Q14678
TLQFGHMSVTVERQM	LAMA5	2836	O15230
HMSVTVERQMIQETK	LAMA5	2841	O15230
EMGFTNMTEIQHKSI	DDX18	196	Q9NVP1
MSVKEQMETIRHGVH	DDX41	301	Q9UJV9
HHAVVGRMQTMVTEQ	FAAP100	801	Q0VG06
MQQMSEQVHTLREEK	GOLGA2	411	Q08379
MEETVRAMTHVINQG	KCNAB2	166	Q13303
MEMRHPNSVQEERKS	NOS1	831	P29475
ELKMMTQLGSHENIV	FLT3	661	P36888
NMMVTGQLGLTEIHK	EFCAB5	1201	A4FU69
HEQDMVNGIMLSVEK	APOB	746	P04114
DKIMSTHGKQIMQAV	ARMC8	546	Q8IUR7
NVVMVNQGLTKHMTV	CCNB1	386	P14635
DQFGHVNMVMVRSLE	ILRUN	121	Q9H6K1
RMVDVMDVNTQKGIE	KDM2A	106	Q9Y2K7
DLTVPQHQEVRGKMM	HS1BP3	21	Q53T59
GDRMTINIQEHMAIN	DOC2A	6	Q14183
TQEVFGRQMAVIMAH	GPR32P1	206	Q8NGA4
IVEMENSGLVHMLKN	CUL3	276	Q13618
KEMVNMRVGVHTGTV	ADCY9	481	O60503
DMVNQMTEKVGLVHG	UGCG	156	Q16739
RATVERMGLMKANHV	FADS1	116	O60427
MVEKMNLTFHVINTG	ITGA4	801	P13612
PIDEVKVRHQMDTMA	INO80D	96	Q53TQ3
QREVSMVEGRVSHME	EMILIN2	696	Q9BXX0
VEIMGHLMAVKERQS	DNAH9	1146	Q9NYC9
HMKATVRHEMTEGVT	DNAH9	1686	Q9NYC9
QKEDRVQTVSMHGLM	CCDC168	4756	Q8NDH2
QIEQLRKMMLSHEGV	CCDC158	171	Q5M9N0
VQAMMEGSHTKADLR	CPT1B	616	Q92523
RQVMEKRVVMSSGGH	MED1	41	Q15648
VVEKMRHVPSGQIMA	MAP2K6	66	P52564
NILGTHTKVMNMEES	STAT1	381	P42224
KIMIMTDQDQDGSHI	TOP2B	556	Q02880
ETQVKVMSQRHMIDG	TARDBP	156	Q13148
VIRVKGQSFMMHQIR	PUS1	281	Q9Y606
SSMKQMEERLQHSER	RUFY1	496	Q96T51
AMGQVRSQEHVEMLQ	SMG1	3476	Q96Q15
ETVMRQMKRGILHTD	PTPN14	446	Q15678
TVNKRHSLEVMNSMV	PTPN14	636	Q15678
HQRGKMSAEEQLERM	PLEKHA7	1066	Q6IQ23
GMKSPEEMRQQAHIQ	POLR3A	21	O14802
TMMVEKEGQSQHMTE	SCN9A	1531	Q15858
TQHMIQRRIMESVNG	SKIV2L	821	Q15477
GQLHEVREMMNQVEG	OSBPL10	236	Q9BXB5
VMERLKGMVQNHQFS	AKAP17A	51	Q02040
LMIDSRIVMGQHEQK	CHST4	221	Q8NCG5
RQPKHVRGQNVEMSM	ROR1	441	Q01973
AKEIRHVGRMASVNM	RAPGEF2	901	Q9Y4G8
TRMMNQRAIVGHVDL	SLC25A14	261	O95258
SNVAELLHQVSMGMK	ZAP70	436	P43403
GMNNEVMKVLLEHRT	TRPA1	141	O75762
QLEMVSGSIQVLKHM	STX10	166	O60499
HQIRELTAKMETQSM	TRAF6	311	Q9Y4K3
KEHIHIGEMKQTSQM	TBC1D1	461	Q86TI0
EHRVMLVNSMNTVKE	VCL	186	P18206
RAGHMKQVNVVLVVM	NPY4R2	256	P0DQD5
DVVKHMRQDQITNGM	POLR3B	401	Q9NW08
AMTQEAIREHQMAKT	TCEA3	286	O75764
ATRQGHLSMVVQLMK	ZDHHC17	131	Q8IUH5
KIQMEMETVSESGTH	ZNF225	81	Q9UK10
IMIMTDQDQDGSHIK	TOP2A	536	P11388
TPRHKVTEMGQEVTM	TRBV12-5	26	A0A1B0GX78
KMMENHVSQASVTIR	VWA8	381	A3KMH1
VQKVTHDMRQGLHNM	TSHR	721	P16473
SVDHVRVTKNQEMMS	NEB	4371	P20929